What are the common adverse reactions of teriparatide injection?

Teriparatide injection (Teriparatide ) is a drug used to treat osteoporosis. Although it has significant efficacy in increasing bone density and reducing the risk of fractures, like any drug, it may also cause some adverse reactions. Understanding these adverse reactions can help patients and doctors take timely measures during the use of drugs to ensure the safety and effectiveness of treatment.

1. Injection site reaction

Injection site reactions are one of the most common side effects of teriparatide injection. These reactions usually include redness, pain, itching, or hardness of the skin, which may occur at the site of the injection, such as the abdomen or outer thighs. In most cases, these reactions are mild and gradually disappear with continued treatment. To reduce the occurrence of injection site reactions, patients are advised to rotate injection sites and avoid repeated injections at the same site. For more severe reactions, patients should inform their doctor, who may need to adjust their injection technique or take other treatment measures.

2. Hypercalcemia and hypercalciuria

Teriparatide can increase bone density by promoting bone formation, but it may also cause a short-term increase in blood calcium levels. Hypercalcemia is when the concentration of calcium in the blood is too high. Symptoms may include nausea, vomiting, loss of appetite, thirst, frequent urination, constipation, muscle weakness, fatigue, etc. Hypercalciuria is high levels of calcium in the urine, which can lead to kidney stones or other kidney problems. To avoid these problems, patients should have their blood and urinary calcium levels checked regularly while being treated with teriparatide, especially during the initial stages of treatment. If blood calcium is found to be too high, your doctor may adjust the medication dose or suspend treatment.

3. Nausea and headache

Nausea and headache are common systemic adverse effects of teriparatide. These symptoms are usually mild and occur early in treatment. Nausea may be accompanied by a loss of appetite, but most patients experience relief as they adjust to the medication. Headache is also a common side effect, and patients may experience mild or moderate head discomfort. In this case, patients may consider taking symptomatic medications (such as acetaminophen) to relieve symptoms. Of course, specific drug selection should be guided by a physician. If headache or nausea persists or worsens, report it to your doctor, who may need to adjust your treatment or take other measures.

4. Joint pain

Joint pain is one of the common side effects of teriparatide, especially at the beginning or during treatment. Patients may experience pain in their bones and joints, especially in weight-bearing areas such as the spine, hips, or knees. In most cases, this joint pain is temporary and gradually resolves as treatment continues or as the patient adapts to the medication. However, if joint pain seriously affects daily life, patients should communicate with their doctor immediately to evaluate whether the treatment plan needs to be adjusted or other auxiliary drugs can be used to relieve symptoms.

5. Dizziness and palpitations

Teriparatide injection may also cause some adverse reactions in the cardiovascular system. Some patients may experience dizziness or palpitations during treatment, which are often related to changes in blood calcium levels. Elevated blood calcium levels may affect the normal rhythm of the heart, causing palpitations, rapid heartbeat and other problems. Dizziness may be caused by changes in blood pressure or other metabolic changes. Although these symptoms are relatively rare, once they occur, patients should inform their doctor in time. Blood calcium level testing and electrocardiogram and other related examinations may be required to ensure the health of the patient's cardiovascular system.

6. Hyperuricemia

Some patients may develop hyperuricemia, which is high levels of uric acid in the blood, during treatment with teriparatide. This may lead to the development of joint diseases such as gout, especially in patients with a history of gout or abnormal uric acid metabolism. Hyperuricemia may cause joint pain and swelling, usually in joints such as the feet and big toes. Patients should have their uric acid levels monitored regularly during treatment, especially those at risk for gout or high uric acid levels. If uric acid is found to be elevated, the doctor may consider adjusting the treatment plan or even suspending the use of teriparatide.

7. Osteosarcoma risk

Although clinically rare, some studies suggest that teriparatide may be associated with an increased risk of osteosarcoma. Osteosarcoma is a rare malignant bone tumor that mainly occurs in adolescents and young adults, especially those with a family history of abnormal bone development or bone development. However, this risk is not apparent in most clinical patients, so the osteosarcoma risk with teriparatide is generally low. Because of this potential risk, teriparatide is generally not recommended for use in those who have a family history of osteosarcoma or have had osteosarcoma in the past.

In general, the side effects of teriparatide injection are relatively mild and mostly temporary, especially in the early stages of treatment. Most adverse reactions will alleviate after the adaptation period. Patients need to regularly monitor blood calcium, urinary calcium, blood uric acid and other indicators during treatment in order to detect potential risks and take measures in a timely manner. If serious or persistent adverse reactions occur, patients should promptly consult their doctor to adjust the treatment plan or seek other treatment methods. With reasonable monitoring and management, teriparatide can safely and effectively help patients treat osteoporosis and improve their quality of life.